Marksans Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2026 ,inter alia, to consider and approve quarterly results for the Quarter ....
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Marksans Pharma has informed the exchanges that its Board of Directors will meet on February 5, 2026 to consider and approve the unaudited financial results (standalone and consolidated) for the quarter and nine months ended December 31, 2025. This is the Q3 FY26 results announcement. The trading window for designated persons and their immediate relatives has been closed from January 1, 2026 and will reopen 48 hours after the results are announced, i.e., on February 7, 2026. The filing is a standard regulatory disclosure under SEBI LODR Regulation 29, with no financial figures disclosed yet.
No direct impact on shareholders at this stage — this is a procedural notice ahead of the actual Q3 results. Investors should watch the February 5 announcement for the actual numbers, which could move the stock.